QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

AMLX

QT85Amylyx Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
15.67
+0.42+2.75%
OverviewShort InterestFilings
AMLXQT85Amylyx Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
15.67+2.75%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-2.45
Insider Own-
Shs Outstand-
Perf Week12.65%
Market Cap1.27BForward P/E-EPS next Y-1.27Insider Trans-Shs Float-Perf Month23.00%
Enterprise Value1.04BPEG-EPS next Q-0.36Inst Own-Short Float-Perf Quarter11.53%
Income-112821406.00P/S0.00EPS this Y42.46%Inst Trans-Short Ratio-Perf Half Y27.29%
Sales-P/B6.17EPS next Y9.89%ROA-51.13%Short Interest-Perf YTD29.72%
Book/sh-P/C-EPS next 5Y-ROE-55.69%52W High18.61 -15.80%Perf Year194.00%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-57.13%52W Low4.80 226.46%Perf 3Y-
Dividend Est.-EV/EBITDA-7.07Sales past 3/5Y-Gross Margin0.00%Volatility4.49% 3.97%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM66.14%Oper. Margin0.00%ATR (14)0.87Perf 10Y-
Dividend Ex-DateMar 28, 2018Quick Ratio17.85Sales Y/Y TTM243.68%Profit Margin0.00%RSI (14)61.29Recom2.09
Dividend Gr. 3/5Y-Current Ratio17.85EPS Q/Q11.90%SMA2011.25%Beta1.40Target Price27.50
Payout0.00%Debt/Eq0.02Sales Q/Q-SMA503.23%Rel Volume1.11Prev Close15.25
Employees123LT Debt/Eq0.02EarningsAug 06SMA20011.47%Avg Volume1.20MPrice15.67
IPO DateJan 07, 2022Option/ShortYes / YesEPS/Sales Surpr.-8.82% -Net Debt/EBITDA1.51Volume1,327,769Change2.75%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-08-26ReiteratedH.C. Wainwright$28 → $34
Apr-28-26ReiteratedMizuho Securities$19 → $21
Feb-19-26ReiteratedMizuho Securities$18 → $19
Feb-10-26ReiteratedH.C. Wainwright$20 → $28
Oct-29-25ReiteratedMizuho Securities$12 → $16
Oct-16-25ReiteratedRobert W. Baird$10 → $19
Sep-15-25ReiteratedGuggenheimBuy$17 → $25
Jun-24-25InitiatedGuggenheimBuy$17
May-07-25UpgradeLeerink PartnersMarket Perform → Outperform$10
Apr-07-25UpgradeMizuhoNeutral → Outperform
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue299087
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A138142
Gross Profit159-145
Selling, General and Administrative Excl. Other18163114
Research and Development13590104
Other Operating Expense-10142
Operating Income-154-153-315
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)6-9-23
Net Income Before Taxes-164-145-302
Income Taxes400
Consolidated Net Income-166-145-302
Net Income From Continuing Operations-166-145-302
Net Income-166-145-302
EPS (Recurring)-2.44-1.53-4.43
EPS (Basic, Before Extraordinaries)-2.44-1.53-4.43
EPS (Diluted)-2.45-1.53-4.43
EBITDA-160-144-291
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
3.56——
Gross Margin53.18—51.72
Operating Margin-51.51—-362.07
Net Margin-55.52—-347.13
Shares Outstanding689568
Market Capitalization1,0661,148—
Operating Lease Expense
———
Insider Trading Volume
$16.93$14.83$12.74$10.64$8.54● Close Price0.00M0.99M1.98M2.97M3.96MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Firestone KarenDirectorMay 21 '26Buy13.513,80051,33866,900May 26 12:00 AM
Klee Justin B.Co-Chief Executive OfficerMar 02 '26Sale14.4729,282423,7603,334,616Mar 04 12:00 AM
Cohen Joshua BCo-Chief Executive OfficerMar 02 '26Sale14.4829,282424,1203,334,683Mar 04 12:00 AM
Bedrosian Camille LChief Medical OfficerMar 02 '26Sale14.586,46194,205169,295Mar 04 12:00 AM
FRATES JAMES MChief Financial OfficerMar 02 '26Sale14.527,909114,851165,638Mar 04 12:00 AM
Mazzariello GinaChief Legal OfficerMar 02 '26Sale14.526,84499,378134,430Mar 04 12:00 AM
Mazzariello GinaChief Legal OfficerFeb 23 '26Sale14.143,41948,352141,274Feb 25 12:00 AM
FRATES JAMES MChief Financial OfficerFeb 02 '26Sale14.653,55752,097173,547Feb 04 12:00 AM
Cohen Joshua BCo-Chief Executive OfficerFeb 02 '26Sale14.6815,500227,5933,363,965Feb 04 12:00 AM
Mazzariello GinaChief Legal OfficerFeb 02 '26Sale14.653,44850,516144,693Feb 04 12:00 AM
Klee Justin B.Co-Chief Executive OfficerFeb 02 '26Sale14.6915,500227,6183,363,898Feb 04 12:00 AM
Cohen Joshua BCo-Chief Executive OfficerJan 16 '26Sale13.831,97427,2993,379,465Jan 20 12:00 AM
Cohen Joshua BCo-Chief Executive OfficerJan 16 '26Option Exercise7.575,63642,6643,381,439Jan 20 12:00 AM
Klee Justin B.Co-Chief Executive OfficerJan 16 '26Option Exercise7.575,69443,1043,381,393Jan 20 12:00 AM
Klee Justin B.Co-Chief Executive OfficerJan 16 '26Sale13.891,99527,7013,379,398Jan 20 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR